CONTENTS

4 OVERVIEW

4 Drug Overview

5 Product Profiles
5 umbralisib : NHL: Follicular lymphoma (FL)
16 umbralisib : NHL: Diffuse large B-cell lymphoma (DLBCL)

LIST OF FIGURES
9 Figure 1: Umbralisib for follicular lymphoma – SWOT analysis

10 Figure 2: Datamonitor Healthcare’s drug assessment summary of umbralisib for follicular lymphoma

11 Figure 3: Datamonitor Healthcare’s drug assessment summary of umbralisib for follicular lymphoma

13 Figure 4: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country, 2017–26

19 Figure 5: Umbralisib for diffuse large B-cell lymphoma – SWOT analysis

20 Figure 6: Datamonitor Healthcare’s drug assessment summary for umbralisib in diffuse large B-cell lymphoma

21 Figure 7: Datamonitor Healthcare’s drug assessment summary for umbralisib in diffuse large B-cell lymphoma

23 Figure 8: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country, 2017–26

LIST OF TABLES
6 Table 1: Umbralisib drug profile

7 Table 2: Umbralisib ongoing pivotal trials in follicular lymphoma

8 Table 3: Umbralisib clinical trial data in follicular lymphoma

14 Table 4: Umbralisib sales for follicular lymphoma across the US and five major EU markets, by country ($m), 2017–26

16 Table 5: Umbralisib drug profile

18 Table 6: Umbralisib ongoing pivotal trial in diffuse large B-cell lymphoma
24 Table 7: Umbralisib sales for diffuse large B-cell lymphoma across the US and five major EU markets, by country ($m), 2017–26